About this document

Liposomal Irinotecan A Review in Metastatic Pancreatic Adenocarcinoma 2020 by ljlj66 is a document available to read on EtoBox.

Liposomal irinotecan (nal-IRI) is an innovative treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) that improves survival outcomes when combined with 5-fluorouracil and leucovorin in patients previously treated with gemcitabine. The NAPOLI-1 trial demonstrated a significant median overall survival advantage of approximately two months for nal-IRI plus 5-FU/LV compared to 5-FU/LV alone, with a manageable safety profile. Real-world studies further support the efficacy and safety of this combina

Author

ljlj66

Language

EN